The Question That Divided Medical Professionals
When Sarah, a 34-year-old critical care nurse working rotating shifts, posted a simple question in a private physician forum, she never expected the flood of responses that would follow. Her query was straightforward: “I get amazing sleep when I occasionally take a benzodiazepine, but I know it is not good for long-term use. What should I actually be taking for sleep with my rotating schedule?”
What emerged was a fascinating glimpse into how medical professionals themselves grapple with sleep issues and the medications they recommend (or avoid) for their patients. The discussion revealed deep divisions, strong opinions, and a surprising consensus on several key points that every patient struggling with sleep should understand.
This article distills those professional insights, combined with the latest peer-reviewed research, to help you make informed decisions about your sleep health.
4 Key Takeaways
- Benzodiazepines like Xanax may feel effective, but they suppress crucial deep sleep and REM stages while carrying significant risks of dependence and cognitive decline with regular use.
- Trazodone emerged as the most frequently recommended prescription alternative among physicians, with many reporting positive patient outcomes for both sleep initiation and maintenance.
- Newer orexin receptor antagonists (Dayvigo, Belsomra, Quviviq) are gaining favor among sleep specialists as potentially safer long-term options that do not disrupt sleep architecture.
- Cognitive Behavioral Therapy for Insomnia (CBT-I) remains the gold-standard first-line treatment, producing lasting improvements without medication side effects.
Why Benzodiazepines Feel Like They Work
Sarah is not alone in her experience. Many patients report that benzodiazepines like alprazolam (Xanax), clonazepam (Klonopin), or diazepam (Valium) provide what feels like the best sleep they have ever had. One physician in the discussion acknowledged this phenomenon, stating: “The only time I truly get amazing sleep is after I take a rare Xanax. Full 8 hours feeling completely rejuvenated.”
However, this apparent effectiveness is misleading. As another medical professional explained: “Xanax works wonderfully in the short run and you may not even notice any change in deep sleep or REM in the short run, but when used chronically, all benzos tend to diminish deep sleep and REM sleep. Plus it is habit forming and it can produce tolerance rather quickly. It may seem ideal, but this is a false savior.”
The Science Behind the Problem
Benzodiazepines work by enhancing the activity of GABA, the brain’s primary inhibitory neurotransmitter. While this produces sedation, it fundamentally alters sleep architecture in ways that compromise restorative sleep.
Research published in the Lancet (2022) confirms that benzodiazepines and Z-drugs (like Ambien) modulate inhibitory neurotransmission in the brain, which can cause cognitive impairment affecting learning, attention, and memory. The study notes that placebo-controlled randomized studies of benzodiazepines have generally been limited to short periods (4 weeks or less), meaning their safety for longer-term use has not been established.
A comprehensive network meta-analysis published in Translational Psychiatry (2024) further explains that approximately half of patients who use benzodiazepines for more than one month develop dependence. The FDA has mandated product label warnings that benzodiazepines and Z-drugs could lead to physical dependence and induce sleep-related complex behaviors while not fully awake.
The Dementia Connection
Perhaps the most concerning risk associated with benzodiazepine use is its potential link to dementia. Multiple meta-analyses have examined this relationship:
An umbrella review published in Current Neuropharmacology (2023) analyzed multiple meta-analyses and found that benzodiazepine users had a significantly increased dementia risk. One included meta-analysis of 10 observational studies found an odds ratio of 1.78 for dementia among benzodiazepine users compared to non-users. Another meta-analysis of 11 studies including nearly 1 million adults showed a pooled odds ratio of 1.38 for dementia association.
However, the relationship is complex. A large population-based study from the Rotterdam Study (2024) published in Alzheimer’s Research & Therapy found that while overall benzodiazepine use was not associated with dementia risk (HR 1.06), high cumulative doses of anxiolytic benzodiazepines specifically showed a stronger association (HR 1.33). The study also found that current benzodiazepine use was associated with lower brain volumes of the hippocampus, amygdala, and thalamus, and accelerated volume loss over time.
As one physician in the discussion astutely noted: “Cognitive decline is also associated directly with poor sleep, so how can one tell if the decline is from the medication itself rather than the poor sleep?” This highlights the challenge in distinguishing medication effects from the underlying conditions being treated.
What Doctors Recommend Instead
Given the concerns about benzodiazepines, what do physicians actually recommend to their patients? The discussion revealed several clear favorites:
1. Trazodone: The Most Recommended Alternative
Trazodone, an antidepressant with sedating properties, emerged as the most frequently mentioned alternative in the physician discussion. One psychiatrist noted: “I have a ton of patients who benefit but definitely not all.” Another physician stated: “Trazodone works wonders for me” in their personal experience.
A family medicine physician from Canada shared: “I find it works fantastic in the perimenopause/menopause group and usually only prescribe it then.” Others reported using doses ranging from 50-200mg, with one noting: “Using 100 mg trazodone nightly for sleep for years. Works in about 20 minutes.”
The research supports these clinical observations. A systematic review and meta-analysis published in PubMed (2024) examining 44 RCTs with nearly 4,000 participants found that trazodone improved sleep quality (SMD = -0.58), reduced nocturnal awakenings (SMD = -0.57), and decreased time awake after sleep onset by an average of 13.47 minutes. Objective total sleep time measured by polysomnography increased by nearly 28 minutes.
However, trazodone is not without drawbacks. The same meta-analysis found higher dropout rates due to adverse effects, with common side effects including somnolence, dry mouth, and in some cases, orthostatic hypotension. As one physician noted: “Dry mouth is significant from it in my experience.”
2. Doxepin: For Sleep Maintenance
Doxepin, a tricyclic antidepressant used at low doses for insomnia, received multiple recommendations. One physician enthusiastically recommended “Doxepin baby” as their first choice. Another provided detailed guidance: “Doxepin 3-50mg: sleep maintenance med, can take nightly for some time until your sleep patterns are re-established, usually does not make one sleepy enough to fall asleep.”
The Lancet network meta-analysis (2022) found that doxepin was well tolerated, though data on efficacy was limited compared to other agents.
3. Orexin Receptor Antagonists: The Newer Option
Several physicians expressed enthusiasm for the newer class of dual orexin receptor antagonists (DORAs), including lemborexant (Dayvigo), suvorexant (Belsomra), and daridorexant (Quviviq).
One physician explained: “The orexin receptor drugs like Dayvigo (lemborexant) are interesting options for people who are refractory to all other sleep aids and sleep hygiene remedies. They are new, are expensive, and given we do not have years of data, a relative unknown but potentially safer than long term benzos.”
A psychiatrist in the discussion endorsed this class as “the correct answer,” noting: “These meds are superior for sleep and having promising data that they can help prevent dementia in the long run.”
The evidence supports these views. A systematic review and network meta-analysis published in Nature (2025) comparing daridorexant, lemborexant, and suvorexant found that all active treatments outperformed placebo for sleep onset and total sleep time. Importantly, the authors noted: “Considering that there is no evidence that DORAs are associated with physiological tolerance, withdrawal symptoms, or rebound insomnia when abruptly discontinued, and that sleep architecture is not adversely affected, the DORAs appear to be a favorable choice in managing insomnia disorder in adults.”
Another network meta-analysis published in Neuropsychopharmacology Reports (2021) recommended 5mg lemborexant as an initial treatment, with escalation to 10mg or switching to suvorexant if needed.
The main downside? Cost. As one physician noted: “The only downside, and a major downside, is the cost.” However, some patients have found success with manufacturer coupons, with one reporting: “The coupon made this $10 for me! It is amazing.”
The Gold Standard: CBT-I
While medications can play a role, the overwhelming consensus among sleep specialists is that Cognitive Behavioral Therapy for Insomnia (CBT-I) should be the first-line treatment for chronic insomnia.
One physician in the discussion emphasized: “CBT-I is more effective than medications and has no side effects.” Another outlined a clear treatment hierarchy: “If I use anything it is usually melatonin/ramelteon, trazodone or doxepin followed by an orexin antagonist if the first two steps failed.”
The evidence for CBT-I is robust. A systematic review and meta-analysis published in JAMA Internal Medicine (2025) analyzing 67 RCTs with over 5,000 participants found that CBT-I was significantly associated with improved insomnia severity (g = 0.98), sleep efficiency (g = 0.77), and sleep onset latency (g = 0.64) with moderate to large effect sizes. Treatment satisfaction was high, with a mean dropout rate of only 13.3%.
According to research published in PMC (2021), approximately 70-80% of those who complete a CBT-I course achieve a therapeutic response, and approximately 40% achieve clinical remission. Importantly, these benefits persist long-term, with one randomized controlled trial showing benefits lasting up to 10 years after treatment.
A psychiatrist in the discussion provided this comprehensive overview: “Good sleep hygiene, and then possibly upgrade to CBT-I is always the most effective, long-term approach to sleep issues, if sleep apnea etc. is not the primary factor.”
Accessing CBT-I
Despite its effectiveness, CBT-I remains underutilized due to a shortage of trained providers. However, digital CBT-I options are expanding access. A nationwide decentralized randomized controlled trial published in JMIR Mental Health (2025) found that FDA-authorized digital CBT-I (SleepioRx) produced statistically and clinically significant improvements in insomnia severity compared to sleep hygiene education alone, with effects sustained at 6-month follow-up.
Natural and Over-the-Counter Options
The physician discussion also included numerous recommendations for non-prescription approaches:
Melatonin: Popular but Controversial
Melatonin was frequently mentioned, with one physician noting: “This is how I survived residency.” However, opinions on its effectiveness varied widely.
A word of caution emerged regarding new research: “New data linking melatonin to cardiovascular disease and death.” However, others questioned this association, noting confounding factors. The Lancet network meta-analysis (2022) found that melatonin “did not show overall material benefits” for insomnia treatment.
Quality control is another concern. One physician noted: “90% of melatonin on the market is garbage.” Recommended brands that consistently pass independent testing include Jarrow and Source Naturals.
Magnesium
Magnesium, particularly glycinate and threonate forms, received multiple recommendations. However, responses were individualized: “Magnesium works wonders for me. So crazy how each individual has such unique chemistry,” noted one physician. Another found it made their mind race.
Theanine and Herbal Options
L-theanine (200mg) was mentioned as a favorite by one physician, who recommended taking it after night shifts to counteract caffeine effects. Kava kava tea was also mentioned, though with cautions about liver toxicity.
One physician offered this practical advice: “The combo of Liposomal GABA + theanine is highly bioavailable. Since GABA is not a direct CNS depressant, I suspect it relaxes you enough that you fall asleep without the potential risk of a direct CNS depressant.”
When Shift Work Is the Real Problem
For Sarah and others working rotating shifts, the discussion highlighted an important truth: sometimes the problem is not insomnia requiring medication, but an environmental issue disrupting the body’s natural circadian rhythms.
A psychiatrist explained this clearly: “Rotating schedules is a mood/limbic system destabilizer. Your body’s circadian clock is essentially jet lagged often and constantly trying to find balance that it cannot. An occasional Xanax is not a huge issue, essentially you are temporarily inhibiting the system’s attempt to restabilize which gives you that rest, but it is not a good long-term solution. Ultimately, this is most likely an external environmental problem, the insomnia is secondary.”
Another physician who had personally experienced shift work challenges shared: “I used to take diazepam 5mg after working shifts and I felt like a million bucks when I woke up. Everyone says it is awful but I never felt so good. Of course, no one will give me that anymore! I quit doing shift work actually. I do not think I could do it without a medicine to help me sleep during the day. Of course, as a prescribing doctor, I worry about dementia with benzos and things. But personally, I was much more worried in the moment about killing myself or someone else because I was exhausted.”
This highlights the genuine dilemma faced by shift workers: the immediate safety risk of severe sleep deprivation versus the long-term risks of sleep medications.
Practical Strategies for Shift Workers
The discussion yielded several practical recommendations:
- Consider dedicated night shifts rather than rotating schedules, if possible
- Use bright light exposure strategically to help reset circadian rhythms
- Maintain a consistent sleep environment with blackout curtains and white noise
- Time caffeine carefully, avoiding it in the latter part of shifts
- Consider working with a sleep specialist experienced with shift work disorder
The Bottom Line: A Patient’s Decision Framework
Based on the collective wisdom of the physician discussion and current research evidence, here is a practical framework for patients struggling with sleep:
Step 1: Rule Out Underlying Causes
Before considering any sleep medication, ensure you have evaluated for sleep apnea, restless leg syndrome, medication side effects, and mental health conditions like depression or anxiety that may be contributing to sleep problems.
Step 2: Optimize Sleep Hygiene
Implement consistent sleep schedules, create a sleep-conducive environment, limit screen exposure before bed, and avoid caffeine and alcohol in the evening.
Step 3: Consider CBT-I
If insomnia persists, seek out CBT-I, either in-person or through FDA-authorized digital platforms. This addresses the underlying perpetuating factors of chronic insomnia.
Step 4: Medication If Needed
If medication is necessary, the evidence suggests considering:
- Trazodone (50-100mg) as a first-line pharmacological option
- Low-dose doxepin (3-6mg) for sleep maintenance issues
- Orexin receptor antagonists (lemborexant, suvorexant, daridorexant) if first-line options fail
- Melatonin (0.5-3mg, 1-2 hours before bed) for circadian rhythm issues
About Benzodiazepines
If you are currently using benzodiazepines for sleep, discuss a tapering plan with your physician. The evidence suggests that occasional use (once a month or less) carries lower risk, but regular use should be avoided due to dependence, cognitive effects, and potential dementia risk.
As one psychiatrist in the discussion pragmatically noted: “Do not overanalyze. You use it rarely and it works? Fine. Live on!” But the key word here is rarely.
Final Thoughts
The physician discussion revealed something important: even medical experts disagree on the best approach to insomnia. What works for one person may not work for another. The key is finding a knowledgeable healthcare provider who can help you navigate the options and find an approach that works for your specific situation.
As one physician summarized: “Shift work is horrible for us and probably no single magic bullet.” The goal is not perfect sleep every night, but finding a sustainable approach that balances effectiveness, safety, and your individual circumstances.
If you are struggling with chronic insomnia, consider reaching out to a sleep specialist who can provide personalized guidance based on the latest evidence and your unique health profile.
References
- De Crescenzo F, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170-184.
- Kishi T, et al. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. Neuropsychopharmacol Rep. 2021;41(4):450-458.
- Kishi T, et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Transl Psychiatry. 2025;15(1):34.
- Islam MM, et al. Benzodiazepine Use and the Risk of Dementia in the Elderly Population: An Umbrella Review of Meta-Analyses. Curr Neuropharmacol. 2023;21(11):2184-2196.
- Billioti de Gage S, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205.
- Tieleman J, et al. Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study. Alzheimers Res Ther. 2024;16(1):12.
- Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis. PubMed. 2024. PMID: 39123094.
- Hameed AK, et al. The efficacy and safety of trazodone for sleep problems in depressive patients: a GRADE-assessed systematic review and meta-analysis of clinical trials. Psychopharmacology (Berl). 2025.
- Edinger JD, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(2):263-298.
- Qaseem A, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133.
- Manber R, et al. Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2025.
- Espie CA, et al. The Effectiveness of Digital Cognitive Behavioral Therapy to Treat Insomnia Disorder in US Adults: Nationwide Decentralized Randomized Controlled Trial. JMIR Ment Health. 2025;12:e84323.
- Morin CM, Benca R. Chronic insomnia. Lancet. 2012;379(9821):1129-1141.
- Jaffer KY, et al. Trazodone for Insomnia: A Systematic Review. Innov Clin Neurosci. 2017;14(7-8):24-34.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The content is based on peer-reviewed research and professional opinions shared in a medical discussion forum. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication or treatment for sleep disorders. Individual circumstances vary, and what works for one person may not be appropriate for another.
About This Guide
This patient education guide was developed by synthesizing insights from medical professionals across multiple specialties, including psychiatry, family medicine, anesthesiology, and emergency medicine, combined with a comprehensive review of current peer-reviewed literature. Our goal is to provide evidence-based information to help patients make informed decisions about their sleep health in partnership with their healthcare providers.
